Jupiter Endovascular, a medical technology startup developing a new class of endovascular procedures using its proprietary Transforming Fixation (TFX) technology, today announced it has closed an oversubscribed Series B financing that surpassed its $40 million target. The round was led by Sonder Capital, with participation from Senvest Management, LB Investment, and a new strategic corporate investor. The proceeds will be used to complete Jupiter's ongoing SPIRARE II pivotal clinical trial, prepare for commercialization, and develop new clinical applications for its TFX platform technology.

Jupiter Endovascular is a medical technology startup developing a new class of endovascular interventions powered by its proprietary Transforming Fixation (TFX) platform technology. The TFX-enabled procedure is designed to bring unmatched stability, control, and anatomical protection to catheter-based therapies. By allowing interventionalists to navigate flexibly through the vasculature and then stabilize with precise control at the treatment site while remaining conformed to the anatomy, Jupiter aims to expand the boundaries of endovascular medicine. Jupiter is initially focused on pulmonary embolism, with plans to expand into additional high-need cardiovascular applications.